Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandre Evrard

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Clinical Pharmacology and Therapeutics|October 13, 2020
Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast CancerAlicja Puszkiel, Cécile Arellano, Christelle Vachoux, et al.
British Journal of Cancer|November 29, 2024
ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironmentMarine Bruciamacchie, Véronique Garambois, Nadia Vie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposureAntonin Schmitt, Laurence Gladieff, Céline M Laffont, et al.
Clinical Pharmacology and Therapeutics|November 25, 2024
French-Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of MavacamtenLouis Lebreton, Jean-Christophe Boyer, Claire Lafay-Chebassier, et al.
Bulletin Du Cancer|March 1, 2018
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks]Marie-Anne Loriot, Joseph Ciccolini, Fabienne Thomas, et al.
Plos One|May 9, 2017
New advances in DPYD genotype and risk of severe toxicity under capecitabineMarie-Christine Etienne-Grimaldi, Jean-Christophe Boyer, Christophe Beroud, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Clinical Pharmacology and Therapeutics|October 13, 2020
Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast CancerAlicja Puszkiel, Cécile Arellano, Christelle Vachoux, et al.
British Journal of Cancer|November 29, 2024
ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironmentMarine Bruciamacchie, Véronique Garambois, Nadia Vie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposureAntonin Schmitt, Laurence Gladieff, Céline M Laffont, et al.
Clinical Pharmacology and Therapeutics|November 25, 2024
French-Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of MavacamtenLouis Lebreton, Jean-Christophe Boyer, Claire Lafay-Chebassier, et al.
Bulletin Du Cancer|March 1, 2018
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks]Marie-Anne Loriot, Joseph Ciccolini, Fabienne Thomas, et al.
Plos One|May 9, 2017
New advances in DPYD genotype and risk of severe toxicity under capecitabineMarie-Christine Etienne-Grimaldi, Jean-Christophe Boyer, Christophe Beroud, et al.
Pageof 7